Expanded Access to Weight-Loss Medications under Medicare Program
Last week, a federal pilot initiative expanded access to weight-loss medications for older individuals enrolled in Medicare. Previously limited to conditions like sleep apnea or cardiac issues, the initiative now allows medications such as Wegovy, Zepbound, and Foundayo to be available for those with obesity under specific Medicare plans. With reduced costs of $50 per month, this program continues through the end of next year.
Healthcare professionals are noting rising enthusiasm among patients, though caution regarding the differing risk profiles in older adults is advised. Dr. Rozalina McCoy from the University of Maryland School of Medicine underscores that older individuals face greater risk potentials. Significant weight loss can lead to muscle reduction, posing concerns about decreased independence and increased fall risks among this demographic.
Kathryn Nicole Porter Starr of Duke University highlights these issues, noting that muscle loss could exacerbate dependence in older adults. Additionally, rapid weight loss can lead to decreased bone density, raising osteoporosis risks, particularly for postmenopausal women. Although strength training may help counteract these effects, it may not be a viable option for all older adults.
The appetite suppression from these medications could also reduce thirst, impacting kidney function and elevating fall risks in a population already prone to dehydration. This can further affect muscle maintenance as reduced hunger might lead to lower protein intake. Moreover, weight-loss medications can alter how the body processes other drugs, necessitating adjustments in dosage for treatments like thyroid hormone replacements or blood pressure medications.
As this program's future beyond the current deadline remains uncertain, there are concerns about continued affordability and access. Without these medications, weight regain is common, yet previous muscle levels might not be recovered. Dr. Tannaz Moin from UCLA warns that this transition could leave older adults weaker than before. Doctors and patients are advised to plan for tapering off medications as the program concludes, ensuring a managed transition.
The outcome of the pilot program could have broader implications for Medicare's policy on obesity drug coverage. Dr. Moin emphasizes the importance of ensuring that these medications remain accessible and affordable, thereby preventing abrupt service interruptions for patients reliant on these treatments.